CJC-1295 + Ipamorelin: The Physiological GH Pulse Stack
A single-vial blend pairing short-acting CJC-1295 (no-DAC) with Ipamorelin for a clean, physiological GH pulse in one shot.
What is CJC-1295 (no-DAC) + Ipamorelin Blend?
A single-vial blend pairing short-acting CJC-1295 (no-DAC) with Ipamorelin for a clean, physiological GH pulse in one shot.
Quick facts
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
Doses shown are those reported in published research, not a recommendation.
What the evidence supports
| Claim | Grade | Basis |
|---|---|---|
| Sleep Quality | Dgrade | no human sleep study of either compound or the combination; mechanistic inference only |
| Muscle Growth | Cgrade | no trial of the combination exists; extrapolated from component data |
| Body Composition | Dgrade | no trial of the combination exists; extrapolated from component data |
| Skin & Aesthetics | Dgrade | no trial of the combination exists; extrapolated from component data |
| Immune Function | Dgrade | no trial of the combination exists; extrapolated from component data |
CJC-1295 (no-DAC) + Ipamorelin Blend Mechanism of Action
GHRH Receptor Activation
CJC-1295 mimics the action of endogenous growth hormone-releasing hormone by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. This triggers synthesis and secretion of growth hormone while preserving natural feedback systems, unlike exogenous GH administration which suppresses endogenous production.
Cycling Guidelines
Most practitioners recommend cycling CJC-1295 to prevent receptor desensitization and maintain the body's responsiveness to the peptide. A common approach involves 8–12 weeks on, followed by 4–8 weeks off. Some users employ a 5 days on, 2 days off weekly schedule with the non-DAC version to preserve pulsatile release patterns.
CJC-1295 + Ipamorelin
This is the most popular combination. Ipamorelin is a growth hormone secretagogue that works through the ghrelin receptor, providing a complementary mechanism to CJC-1295's GHRH pathway. Together, they produce synergistic GH release greater than either peptide alone. Typical dosing involves 100–300 mcg of each peptide administered together. See the full CJC-1295 vs ipamorelin comparison for more detail.
CJC-1295 + GHRP-6 or GHRP-2
These growth hormone-releasing peptides also work through the ghrelin pathway and can be stacked with CJC-1295. GHRP-6 notably increases appetite, which may be beneficial for those seeking to gain mass. For a comparison of these two GHRPs, see GHRP-2 vs GHRP-6 .
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results
CJC-1295 altered serum protein profiles including apolipoprotein A1 and transthyretin as potential GH/IGF-1 biomarkers. CJC-1295 produced sustained dose-dependent increases in GH and IGF-I levels with good safety profile.
CJC-1295 (no-DAC) + Ipamorelin Blend Dosage and Protocols
Dosage Protocols
No FDA-approved dosing guidelines exist for CJC-1295. The following protocols are derived from clinical research and community reports.
CJC-1295 without DAC (Mod GRF 1-29)
Conservative starting dose: 50–100 mcg per injection Frequency: 1–2 times daily (bedtime dose is considered most important) Timing: Often administered before bed to coincide with natural GH release, and/or upon waking Cycle length: 8–12 weeks, followed by 4 weeks off
CJC-1295 with DAC
Starting dose: 300 mcg per injection twice weekly Maintenance dose: 300–600 mcg once or twice weekly
How to Use / Administration
CJC-1295 is administered via subcutaneous injection , typically into the abdominal fat, thigh, or upper arm. Draw the appropriate dose using an insulin syringe (typically 29–31 gauge) Clean the injection site with an alcohol swab Pinch the skin and insert the needle at a 45-degree angle Rotate injection sites to prevent lipodystrophy For CJC-1295 without DAC, most protocols involve once or twice daily injections. The bedtime dose is considered the most important, as it coincides with the body's natural nocturnal GH surge. A morning dose can be added for those seeking additional effect. For CJC-1295 with DAC, once or twice weekly injections are sufficient due to the extended half-life. Consistency in timing (e.g., every Monday and Thursday) helps maintain stable blood levels.
Reconstitution, Storage & Prep
CJC-1295 is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use. Allow the peptide vial to reach room temperature Using bacteriostatic water (preferred) or sterile water, slowly inject the diluent down the inside wall of the vial, never directly onto the powder Gently swirl the vial until the powder is fully dissolved; do not shake vigorously For a 2 mg vial, adding 2 mL of bacteriostatic water creates a concentration of 1 mg/mL (1000 mcg/mL), making dosing calculations straightforward Unreconstituted powder: Store in a cool, dry place; refrigeration extends shelf life to 24+ months Reconstituted solution: Must be refrigerated at 2–8°C (36–46°F) With bacteriostatic water: Stable for approximately 4–6 weeks refrigerated
CJC-1295 (no-DAC) + Ipamorelin Blend Side Effects and Safety
Safety & Contraindications
CJC-1295 (no-DAC) + Ipamorelin Blend is a research compound and is not FDA-approved for general use. It should be avoided by anyone with active malignancy and pregnancy. Most reported effects are mild and dose-dependent, so start at the low end of the dosing range and titrate up slowly rather than chasing a maximal dose. Injection-site redness, itching, or a temporary lump are the most common local reactions; rotate sites and use clean technique to keep them minimal.
What to Monitor
Track IGF-1, HbA1c, and fasting glucose while you're running CJC-1295 (no-DAC) + Ipamorelin Blend so you can catch any drift early and adjust before it becomes a problem. Add these to your REGEN biomarker dashboard and re-check on your normal cadence.
CJC-1295 (no-DAC) + Ipamorelin Blend Research Evidence
Key Takeaways
CJC-1295 is a lab-made peptide that tells the pituitary gland to release more growth hormone and IGF-1 . It comes in two forms: with DAC , which lasts longer, and without DAC , which wears off much faster. CJC-1295 is not FDA-approved , is banned by WADA, and may carry heart and blood sugar risks. CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Clinical research demonstrated that single injections increase GH levels 2- to 10-fold for six or more days and elevate IGF-1 levels 1.5- to 3-fold for 9–11 days. Enhanced fat metabolism and body composition Improved recovery from exercise and injury Potential anti-aging effects through elevated IGF-1 levels Increased collagen synthesis and skin elasticity
Pulsatile vs. Sustained GH Release
CJC-1295 without DAC produces a more pulsatile pattern of GH release, which some researchers believe better mimics natural physiology. The body normally releases GH in pulses, with the largest occurrence during deep sleep. CJC-1295 with DAC creates more sustained elevation of GH and IGF-1 levels, which may benefit certain therapeutic applications but potentially blunts the natural pulsatile rhythm.
IGF-1 Axis Activation
Beyond direct GH stimulation, CJC-1295 activates the broader GH/IGF-1 axis. Elevated GH stimulates the liver to produce IGF-1, which mediates many of growth hormone's anabolic effects on muscle, bone, and other tissues. Clinical trials showed IGF-1 levels remained elevated above baseline for up to 28 days following multiple doses.
Results Timelines
Weeks 1–2: Most users report improved sleep quality and more vivid dreams. Some experience mild water retention and increased appetite. Weeks 2–4: Enhanced recovery from workouts becomes noticeable. Some users report improved skin quality and minor fat loss. Weeks 4–8: More significant changes in body composition typically emerge, including increased muscle fullness and continued fat reduction. Strength gains may become apparent. Weeks 8–12: Cumulative effects peak, with users often reporting the most dramatic improvements in lean mass, recovery, and overall body composition. Clinical research supports this timeline, showing IGF-1 levels remained elevated above baseline for up to 28 days with repeated dosing, suggesting cumulative benefits.
Research Evidence
The most significant clinical study on CJC-1295 was published in the Journal of Clinical Endocrinology & Metabolism in 2006. This randomized, placebo-controlled, double-blind trial examined pharmacokinetics, pharmacodynamics, and safety in healthy adults aged 21–61. Single injections produced dose-dependent increases in GH concentrations of 2- to 10-fold lasting 6 or more days IGF-1 levels increased 1.5- to 3-fold for 9–11 days after a single dose Multiple doses produced cumulative effects, with IGF-1 remaining elevated above baseline for up to 28 days No serious adverse reactions were reported The peptide was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg Animal Research: A study published in the American Journal of Physiology demonstrated that once-daily administration of CJC-1295 normalized growth in GH-deficient models, supporting its potential therapeutic applications. Additional Study (2009): Research published in Growth Hormone & IGF Research further confirmed the activation of the GH/IGF-1 axis by CJC-1295, establishing its efficacy as a long-acting GHRH analog. Important Note: A Phase II clinical trial investigating CJC-1295 for HIV-associated lipodystrophy was halted in 2006 following a patient death, though the relationship to the study drug was not definitively established.
Legal Status / FDA
CJC-1295 is not FDA-approved for human use. It exists in a regulatory gray area . It can be legally purchased for research purposes only but is not approved for human consumption or medical treatment. In December 2024, the FDA's Pharmacy Compounding Advisory Committee discussed CJC-1295 among other peptides, with the agency expressing concerns about cardiac risks and the potential for peptide impurities in compounded preparations. The FDA has moved to restrict compounding pharmacies from producing certain peptides, including CJC-1295, citing safety concerns and lack of adequate clinical data. Internationally, regulations vary significantly. Some countries permit peptide sales with fewer restrictions, while others classify them as controlled substances. Not FDA-approved for any medical indication Cannot legally be sold as a drug, food, or dietary supplement for human consumption Legally sold as a "research chemical" not intended for human use Compounding pharmacy restrictions were significantly tightened in late 2024
CJC-1295 (no-DAC) + Ipamorelin Blend Stacking and Combinations
Stacking
CJC-1295 is frequently combined with other peptides to enhance its effects.
CJC-1295 + BPC-157
Some users combine CJC-1295 with BPC-157 for enhanced recovery and healing, though this combination lacks clinical research.
Peptide Stacking Guide
Peptide stacking combines two or more peptides in coordinated protocols to achieve synergistic effects for muscle growth, fat loss, recovery, and cognitive enhancement. Learn the most effective stacks, dosing strategies, safety protocols, and monitoring guidelines. “Peptidepedia compiles and maintains peptide information from peer-reviewed research , clinical trials , and verified laboratory data .”
Synergy with Growth Hormone-Releasing Hormone
Ipamorelin's effects are potentiated when the hypothalamus releases endogenous growth hormone-releasing hormone (GHRH). The two pathways work synergistically. GHRH primes the pituitary while ipamorelin amplifies the release signal. This is why many protocols combine ipamorelin with synthetic GHRH analogs like CJC-1295 or Mod GRF 1-29 for enhanced effects.
Advanced Protocol
200 mcg, two to three times daily, often combined with a GHRH analog such as CJC-1295, for 8-12 weeks.
Ipamorelin + CJC-1295 (no DAC) / Mod GRF 1-29
This is the most popular combination. The GHRH analog primes the pituitary while ipamorelin amplifies release, creating a synergistic effect that produces greater GH elevation than either peptide alone. Typical dosing involves equal amounts (e.g., 100 mcg of each) administered simultaneously. See the ipamorelin vs GHRP-6 guide for a comparison of the main GHRP options, or the CJC-1295 vs ipamorelin page for stacking context.
CJC-1295 (no-DAC) + Ipamorelin Blend Pharmacokinetics
Extended Half-Life Through Albumin Binding
DAC technology represents a significant pharmacological advancement. After subcutaneous injection, CJC-1295 with DAC forms a covalent bond with circulating albumin through a reactive maleimido group, protecting the peptide from enzymatic degradation and renal clearance. Research confirmed an estimated half-life of 5.8–8.1 days in healthy adults.
CJC-1295
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog available in two forms: with DAC (Drug Affinity Complex) for extended half-life, and without DAC (MOD GRF 1-29) for more pulsatile release.
The study of doping market: How to produce intelligence from Internet forums.
Analysis of 13 Internet forums identified 327 doping suppliers and detected emerging peptide products including CJC-1295. CJC-1295 demonstrated extended plasma half-life and sustained GH secretion in rats compared to native GRF.
More on CJC-1295 (no-DAC) + Ipamorelin Blend pharmacokinetics
Contraindications
- active malignancy
- pregnancy
Frequently asked questions
What is a typical CJC-1295 (no-DAC) + Ipamorelin Blend dose?
Published research protocols report CJC 100–300 mcg · Ipa 200–300 mcg, 1-2x daily, pre-bed. This is the range described in the literature, not a recommendation.
Is CJC-1295 (no-DAC) + Ipamorelin Blend backed by strong evidence?
CJC-1295 (no-DAC) + Ipamorelin Blend carries a REGEN research grade of C. REGEN Research Tier B — observational human data (cohort / case studies).
How is CJC-1295 (no-DAC) + Ipamorelin Blend administered?
Routes reported in the literature: subcutaneous.
Who should avoid CJC-1295 (no-DAC) + Ipamorelin Blend?
Contraindications noted in the literature include active malignancy, pregnancy.
References
- Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. · Hoffmann P, Feige JJ, Alfaidy N · 2006
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. · Sackmann-Sala L, Ding J, Frohman LA et al. · 2009
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. · Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH · 1998
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. · Beck DE, Sweeney WB, McCarter MD et al. · 2014
- Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem - NIH
- Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005. · Chung S, Son GH, Park SH, Park E, Lee KH, Geum D, Kim K · 2005
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. · Teichman SL, Neale A, Lawrence B et al. · 2006
- Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561. · Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, Kattan MW · 1998
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. · Gobburu JV, Agersø H, Jusko WJ et al. · 1999
- Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006. · Zaidi D, James KA, Wagner GF · 2006
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. · Ionescu M, Frohman LA · 2006